Serious Disparities in Outcomes for Lung Cancer Patients According to Where You Live in Europe
The World Health Organization estimates 387,913 Europeans will die of lung cancer in 2018.1 The preliminary findings from a new study by the Economist Intelligence Unit comparing 13 countries show that governments across Europe are responding in very different ways to the disease. Countries with better outcomes seem to have effective prevention policies in place and prioritize timely access to new, innovative treatments. Initial research from the study, which will run into early 2019 with in-depth country research and workshops, will be presented today by the Economist Intelligence Unit at the European Cancer Forum in Brussels, which is hosted by MSD. The audience of policy-makers, academics, healthcare professionals, industry, and patient representatives, will provide a first sounding-board for the study findings, and help focus the next phase of research. The EIU will be looking to understand whether countries are advancing, innovating and seizing the opportunities to save lives.
Already, the study points to seven key findings from the 13 countries2:
1. For the past 15 years the number of new lung cancer cases has been highest in the Netherlands and lowest in Sweden. The number of deaths caused by lung cancer is highest in Poland, the Netherlands, Belgium, the United Kingdom and Greece – but the numbers have gone down significantly in the past 15 years. Finland has made great progress, and now has the lowest death rate. All other countries have made little to no progress in the past 15 years.
2. We have seen an average increase in the percentage of patients who are still alive 5 years after diagnosis, from 12 percent to only 17 percent over 15 years. The average survival rate for all cancers combined is 50-60 percent.3 Austria, Sweden and Norway have the highest survival rates for lung cancer, with the lowest survival rates occurring in Romania, Finland and the United Kingdom.
3. Lung cancer is a strategic priority in those countries with (lung) cancer control plans and guidelines: Sweden and France score best here, while Finland has some catching up to do.
4. Since smoking is the primary risk factor for lung cancer, with around 80 percent of lung cancers linked to smoking, public health programs around tobacco control and smoking cessation, including regulation of e-cigarettes, are particularly important. The study shows that Finland and Norway lead in this area, while Romania has litte in place.
5. In terms of treatment, the study notes whether patients are getting treatment, tumour testing is available and reimbursed, and new, innovative medicines are reimbursed. Of the four most commonly used biomarkers for lung cancer, testing for all four is only reimbursed in a minority of countries.
6. Only Sweden and Poland have a specific lung cancer plan/section of the National Cancer Control Plan (NCCP), and only four countries (Austria, France, Romania and Greece) have updated their NCCP in the last five years.
7. Only half of the countries (Belgium, France, Germany, Netherlands, Poland,Spain, UK) have started or are involved in a trial to investigate whether or how screening could be introduced.
Giving his reaction ahead of his keynote speech at the European Cancer Forum, Martin Seychell, Deputy Director-General in the Health and Food Safety Directorate General (DG SANTE) of the European Commission, said: “In recent years we have been able to improve outcomes for cancer patients, although cancer remains the second-highest cause of death in the EU”. He added that “The results of the Economist Intelligence Unit study clearly show the need for close collaboration between all stakeholders and fighting this disease will undoubtedly remain a priority for the Commission in the years to come.”
“The country benchmarking and in country analyses in this study point us in the direction of how to achieve better outcomes,” said Alfonso Aguarón on behalf of Lung Cancer Europe. “Policy makers should see these results and be encouraged to take the findings of the report forward. It is time for more awareness around the burden of this disease for patients, their family and friends. It is about time these patients get noticed.”
Deepak Khanna, Senior Vice President and Regional President, EMEAC Oncology for MSD, commented: “All stakeholders should accelerate implementing policies which contribute to better outcomes. As a biopharmaceutical research company, we are working with governments across Europe to ensure patients have timely access to our innovative cancer medicines, to help extend and improve the lives of patients with lung cancer.”
Notes to the Editor
The study is composed of several indicators, with each country being assessed for its performance. The indicators are clustered into five domains4 related to awareness, prevention, screening, diagnosis, treatment and care. Each country has received a rating for each indicator, and the study supports policy makers by providing a handful of recommendations for areas that can be improved. For example, the time from the presentation of symptoms to diagnosis can take several months. The better performing countries have a fast track to diagnosis for suspected lung cancer patients, with guidelines mentioning the fast track and a specific time frame for diagnostic referral.
The Economist Intelligence Unit benchmarking study is being supported by MSD. Editorial decisions are the responsibility of the Economist Intelligence Unit.
The European Cancer Forum is hosted by MSD, in collaboration with Lung Cancer Europe (LUCE) and the European Cancer Patient Coalition (ECPC). It is taking place on 04 December 2018 at the Solvay Library in Brussels.
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information, visit www.msd.com and connect with us on Twitter, LinkedIn and Twitter, LinkedIn and YouTube.
last accessed 30 November 2018
2 Austria, Belgium, Finland, France, Germany, Greece, the Netherlands, Norway, Poland, Romania, Spain, Sweden and the UK
3 6.1 C Allemani and the CONCORD Working Group. (2015) Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385(9972):977–1010 https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(14)62038-9.pdf; https://www.thelancet.com/cms/attachment/2053318878/2060147121/mmc1.pdf, last accessed 30 November 2018
4 These five domains are: (1) lung cancer is a strategic priority, (2) lung cancer is a public health issue, (3) lung cancer is a race against time, (4) lung cancer is possible to address, and (5) lung cancer is ready for innovation.
European Communication Director, MSD: Veronika Bendere
Global Media Relations Director, MSD: Pamela Eisele
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Axonics® Announces Publication of NICE Briefing10.12.2018 19:03 | Tiedote
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today the publication of a Medtech Innovation Briefing by The National Institute for Health and Care Excellence (“NICE”) following a careful review of the innovations offered by the Axonics System. The NICE Medtech Innovation Briefing entitled: “Axonics rechargeable sacral neuromodulation system for overactive bladder and faecal incontinence,” describes published clinical evidence on the Axonics r-SNM System®, confirming efficacy as well as the potential positive economic impact that is possible by the use of the Axonics system in the United Kingdom. The Axonics r-SNM System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe and commercially available to all hospitals and clinics in the U.K. for patients
The Largest Blockchain Conference in Asia to Be Held 30–31 January in Yokohama, Japan10.12.2018 18:00 | Tiedote
The Global Blockchain Association (Shimizu Building 6F, 3-19 Hayabusacho, Chiyoda-ku, Tokyo, President: Toshikazu Masuyama) is proud to host the largest blockchain conference in Asia: The Japan Blockchain Conference (JBC) – 2019 Yokohama, to be held on 30 and 31 January at Pacifico Yokohama. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181210005057/en/ The Japan Blockchain Conference (JBC) - 2019 Yokohama (Graphic: Business Wire) The conference will host top companies and organizations from Japan and abroad who represent the future of the rapidly growing blockchain space. This is the place where the leaders of blockchain and crypto can interact, form partnerships, and showcase their leading technologies and developments. We are actively looking for companies to join the best of the blockchain industry and exhibit at our conference. More details can be found here: http://japan-blockchain-c.com/en/ We welcome a wide range of
Global Payments’ TouchNet Business Named “Partner of the Year” by Ellucian10.12.2018 16:30 | Tiedote
Global Payments Inc. (NYSE: GPN), a leading worldwide provider of payment technology and software solutions is pleased to announce that its TouchNet business was named “Partner of the Year” by Ellucian, a provider of software and services that power higher education, at its Partner Forum reception during the annual EDUCAUSE Conference this year in Denver, CO. TouchNet was recognized for its collaborative efforts to deliver streamlined engaging, cloud-based, student commerce and credential solutions. This honor further demonstrates the depth and breadth of the TouchNet platform and its dedication to delivering software-driven and technology-enabled strategies to institutions of higher education. “TouchNet’s commitment to delivering maximum value enables Ellucian to consistently provide customers with best-in-class solutions, support and service,” said Chris Westfall, Vice President Partnerships Ellucian. “When you combine Ellucian’s feature rich technology and in-depth customer knowledg
CTS Engines Hires Tom Bode as Senior Vice President, Operations10.12.2018 16:00 | Tiedote
CTS Engines, the global leader for mature engine maintenance within the Aerospace & Defense industry, announced today that it had hired Tom Bode as its Senior Vice President, Operations. In his new role, Mr. Bode will be responsible for all operations, quality, and engineering functions, and will report to Vesa Paukkeri, CTS Engines’s President and COO. Since 2008, Mr. Bode has been the General Manager of the Columbus Engine Center for Pratt & Whitney, a company he joined in 2000. Prior to 2000, Mr. Bode worked at GE Aviation, where he was a quality and engineering leader. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181210005036/en/ Tom Bode (Photo: Business Wire) “As the General Manager of CEC, Tom managed over 700 employees across multiple engine production lines and reduced overhaul turnaround times through the promotion of Lean manufacturing principles,” said Mr. Paukkeri. “His performance as a manager was recognized
Tracxpoint Signed a Major Agreement to Deploy its Artificial Intelligence Cart (AiC®) Platform at CONAD, One of the Largest and Most Sophisticated Supermarket Chains in Italy with 3,000 Locations in Lieu of Amazon Go after Intensive Study10.12.2018 14:00 | Tiedote
Tracxpoint, a global provider of next-generation self-checkout grocery solutions, today announced an agreement to roll out its Artificial Intelligence Cart (AiC®) at CONAD DEL TIRRENO, one of the seven cooperatives of CONAD’s chain with more than 3,000 supermarket stores in Italy. This is a major milestone for the Israeli startup in its mission to establish the AiC® platform as the most powerful, accessible and comprehensive solution for self-checkout and personalized in-store engagement on the market today. CONAD DEL TIRRENO will start implementing the AiC® ecosystem during 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181210005176/en/ The Tracxpoint AiC enables checkout-free stores and personalized in-store engagement for Italy's largest supermarket chain, CONAD. (Photo: Business Wire) In direct contrast to capital-intensive and smaller store concepts like Amazon Go or its imitators that rely on ceiling cameras for
Jetex Now the Exclusive Dealer in the Middle East for Hi-Tech New HondaJet10.12.2018 12:52 | Tiedote
Jetex is bringing the next-generation in advanced private jets to the Middle East after striking an agreement with Honda Aircraft Company to become the exclusive authorized dealer for the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181210005273/en/ Adel Mardini of Jetex signs with Simon Roads of Honda Aircraft Company (Photo: AETOSWire) The deal means Jetex is now the manufacturer’s sole representative for the new HondaJet offering sales and support across the Gulf and Middle East region. “With Honda’s brand strength and recognition in the Middle East, we have received tremendous interest in the HondaJet Elite. We are proud to appoint Jetex as HondaJet Middle East to provide our customers with a committed sales team in the region for the world’s most advanced very light jet,” said Honda Aircraft President and CEO Michimasa Fujino. “We are proud to be chosen by Honda Aircraft Company and excited to be awarded the r
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme